Roche Holding AG (0QOK.IL)
| Previous close | 273.10 |
| Open | 275.80 |
| Bid | 276.60 x N/A |
| Ask | 289.70 x N/A |
| Day's range | 275.60 - 284.05 |
| 52-week range | 272.10 - 404.10 |
| Volume | |
| Avg. volume | 543,105 |
| Market cap | 233.055B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 16.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.30 (3.22%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Globe Newswire
[Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee
Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments: Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO Roche Pharmaceuticals based in Basel, Switzerland effective March 2023 and will become a member of the Corporate Executive Committee. At the same time, Levi Garraway, Chief Medical Officer and Executive Vice President, Global Product Development, based
- Globe Newswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023 Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division sales increase by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19) Diagnostics Division sales grow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the d
- Globe Newswire
European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life1The approval is based on the HAVEN 6 results, where Hemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors2 Basel,
